Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act (Hardback)Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and (author), Board on Health Sciences Policy (author), Institute of Medicine (author), Thomas F. Boat (editor), Marilyn J. Field (editor)
Hardback 432 Pages / Published: 13/09/2012
- Not available
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Publisher: National Academies Press
Number of pages: 432
Dimensions: 229 x 152 mm
You may also be interested in...
£53.00Multiple copy pack
Thank you for your reservation
Your order is now being processed and we have sent a confirmation email to you at
When will my order be ready to collect?
Call us on or send us an email at
Unfortunately there has been a problem with your order
Please try again or alternatively you can contact your chosen shop on or send us an email at